It will be interesting to assess whether the IL‐12/15/18‐preactivated NK cells and low‐dose IL‐2, which is known to enhance Treg cells, might be sequentially combined to suppress both acute and chronic GvHD. Here, IL2 is linked to graft versus host disease.